Mast Therapeutics

We are a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. We have built our product pipeline through the strategic acquisition of privately-held companies with clinical-stage assets and we currently are focused on developing new therapies for sickle cell disease, a chronic, genetic disorder classified as a rare, or orphan, disease in the United States and European Union, and for heart failure, a condition with a high unmet need for innovative treatment options.
San Diego, US
Size (employees)
6 (est)-78%
Mast Therapeutics was founded in 1995 and is headquartered in San Diego, US

Mast Therapeutics Office Locations

Mast Therapeutics has an office in San Diego
San Diego, US (HQ)
500 3611 Valley Centre Dr

Mast Therapeutics Data and Metrics

Mast Therapeutics Financial Metrics

Mast Therapeutics's revenue was reported to be $128 k in FY, 2016
$, USD

Revenue (FY, 2016)

128 k

Net income (FY, 2016)

(36.1 m)

EBIT (FY, 2016)

(36.5 m)

Market capitalization (27-Apr-2017)

33.4 m

Closing share price (27-Apr-2017)


Cash (31-Dec-2016)

8.5 m
Mast Therapeutics's current market capitalization is $33.4 m.
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


128 k

Revenue growth, %


R&D expense

12.9 m19.4 m28.3 m20.8 m

Operating expense total

21.5 m29.3 m39.4 m36.6 m


(21.5 m)(29.3 m)(39.4 m)(36.5 m)

EBIT margin, %


Interest income

60.3 k69 k130 k122 k

Pre tax profit

(21.5 m)(28.7 m)(39.8 m)(38.5 m)

Net Income

(21.5 m)(28.7 m)(39.8 m)(36.1 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


25.7 m35.8 m23.1 m8.5 m


1.1 m1.1 m1.3 m903 k

Current Assets

45.5 m58.4 m42.3 m12.2 m


105.7 k188 k226 k99 k


3 m3 m3 m3 m

Total Assets

55.2 m70.5 m54.2 m17.9 m

Accounts Payable

963.9 k1.4 m2.6 m626 k

Current Liabilities

4.8 m8.4 m23.2 m4.9 m

Additional Paid-in Capital

254.2 m293.7 m298.7 m320.6 m

Retained Earnings

(235.1 m)(275 m)(311.1 m)

Total Equity

47.8 m58.7 m23.9 m9.8 m

Financial Leverage

1.2 x1.2 x2.3 x1.8 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(21.5 m)(28.7 m)(39.8 m)(36.1 m)

Depreciation and Amortization

39.5 k85 k146 k99 k

Cash From Operating Activities

(17.8 m)(24.6 m)(32.9 m)(37.3 m)

Purchases of PP&E

(46.8 k)(147 k)(165 k)(8 k)

Cash From Investing Activities

(4.8 m)481 k3.4 m15.2 m

Cash From Financing Activities

25.7 m34.3 m16.8 m7.6 m
$, USDY, 2016


4.6 k

Financial Leverage

1.8 x

Mast Therapeutics Market Value History

Mast Therapeutics Online and Social Media Presence

Mast Therapeutics Company Life and Culture

You may also be interested in